Leerink Partnrs Has Negative Outlook of DNLI FY2025 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for Denali Therapeutics in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($3.45) per share for the year, down from their previous estimate of ($2.80). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.74) per share. Leerink Partnrs also issued estimates for Denali Therapeutics' FY2026 earnings at ($2.40) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at ($0.55) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the previous year, the business earned ($0.72) earnings per share.

A number of other equities analysts have also issued reports on DNLI. JPMorgan Chase & Co. decreased their price objective on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. Cantor Fitzgerald lowered Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, October 7th. Stifel Nicolaus raised shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price objective for the company in a report on Monday, December 16th. The Goldman Sachs Group lowered their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Finally, Robert W. Baird assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an "outperform" rating and a $31.00 price objective on the stock. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.00.

Denali Therapeutics Trading Up 5.3 %

NASDAQ:DNLI traded up $1.16 during mid-day trading on Friday, hitting $23.00. The stock had a trading volume of 705,069 shares, compared to its average volume of 1,013,701. The company has a 50 day simple moving average of $22.37 and a 200-day simple moving average of $24.85. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33. The stock has a market capitalization of $3.31 billion, a price-to-earnings ratio of -8.33 and a beta of 1.43.

Insider Activity at Denali Therapeutics

In other news, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now owns 25,757 shares in the company, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the sale, the chief executive officer now directly owns 260,721 shares of the company's stock, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,518 shares of company stock worth $1,469,382 in the last quarter. 7.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. raised its holdings in shares of Denali Therapeutics by 163.7% during the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company's stock worth $1,162,000 after acquiring an additional 24,767 shares in the last quarter. FMR LLC raised its stake in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after purchasing an additional 7,596,508 shares in the last quarter. Algert Global LLC lifted its holdings in shares of Denali Therapeutics by 82.4% during the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company's stock valued at $1,417,000 after buying an additional 21,975 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock valued at $6,857,000 after buying an additional 14,324 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after buying an additional 149,939 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.